Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Major Depressive Disorder (MDD)Current evidence has consistently shown that IV ketamine may improve symptoms scored by the MADRS and HAM-D scoring tools at 24 hours in patients with MDD. However, identifying which patients are most likely to respond and the duration of response remains unknown.Post-Traumatic Stress Disorder (PTSD)There remains a paucity of good quality evidence to fully support IV ketamine in patients experiencing PTSD as only one randomized controlled trial (RCT) was identified. This is a new area for the use of a NMDA receptor antagonist and while current evidence is optimistic, more evidence with validated outcomes is required to ascertain the clinical effectiveness of IV ketamine in PTSD. Suicidal IdeationCurrent evidence suggests that IV ketamine may be a benefit for components of depression scoring tools related to suicidal ideation, however identifying which patients would benefit is difficult. More trials of higher quality that investigate hard outcomes such as suicide attempts and using patients at risk of imminent suicide are required to determine clinical effectiveness of IV ketamine in suicidal ideation. Indexing Status Subject indexing assigned by CRD MeSH Administration, Intravenouss; Antidepressive Agents; Depressive Disorder, Major; Infusions, Intravenous; Ketamine; Mental Disorders; Receptors, N-Methyl-D-Aspartate; Stress Disorders, Post-Traumatic; Suicidal Ideation Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000190 Date abstract record published 04/03/2015 |